327 related articles for article (PubMed ID: 33569985)
21. Future therapeutic options for patients with Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Argyropoulos K; Palomba ML; Treon SP
Best Pract Res Clin Haematol; 2016 Jun; 29(2):206-215. PubMed ID: 27825467
[TBL] [Abstract][Full Text] [Related]
22. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
[TBL] [Abstract][Full Text] [Related]
23. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
Moreno DF; Fernández de Larrea C
Hematol Oncol Clin North Am; 2023 Aug; 37(4):659-670. PubMed ID: 37211494
[TBL] [Abstract][Full Text] [Related]
24. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
[TBL] [Abstract][Full Text] [Related]
25. Emerging drugs for the treatment of Waldenström macroglobulinemia.
Despina F; Meletios Athanasios D; Efstathios K
Expert Opin Emerg Drugs; 2020 Dec; 25(4):433-444. PubMed ID: 32955949
[TBL] [Abstract][Full Text] [Related]
26. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
Amaador K; Kersten MJ; Minnema MC; Vos JMI
Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
[TBL] [Abstract][Full Text] [Related]
27. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
Thomas SK
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
[TBL] [Abstract][Full Text] [Related]
28. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
29. Toward personalized treatment in Waldenström macroglobulinemia.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):365-370. PubMed ID: 29222280
[TBL] [Abstract][Full Text] [Related]
30.
Alcoceba M; García-Álvarez M; Medina A; Maldonado R; González-Calle V; Chillón MC; Sarasquete ME; González M; García-Sanz R; Jiménez C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628381
[TBL] [Abstract][Full Text] [Related]
31. Waldenström Macroglobulinemia and Non-IgM-Type Lymphoplasmacytic Lymphoma Are Genetically Similar.
Awata-Shiraiwa M; Yokohama A; Kanai Y; Gotoh N; Kasamatsu T; Handa H; Saitoh T; Murakami H; Hirato J; Ikota H; Tsukamoto N
Acta Haematol; 2023; 146(5):384-390. PubMed ID: 36917966
[TBL] [Abstract][Full Text] [Related]
32. How I treat Waldenström macroglobulinemia.
Dimopoulos MA; Kastritis E
Blood; 2019 Dec; 134(23):2022-2035. PubMed ID: 31527073
[TBL] [Abstract][Full Text] [Related]
33. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.
Landgren O; Tageja N
Leukemia; 2014 Sep; 28(9):1799-803. PubMed ID: 24573383
[TBL] [Abstract][Full Text] [Related]
34. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
35. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
36. Advances in Treatment of Waldenström Macroglobulinemia.
Durot E; Tomowiak C
Curr Oncol Rep; 2023 Nov; 25(11):1375-1386. PubMed ID: 37855849
[TBL] [Abstract][Full Text] [Related]
37. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
Varettoni M; Matous JV
Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
[TBL] [Abstract][Full Text] [Related]
38. Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.
Poulain S; Herbaux C; Bertrand E; Decambron A; Fouquet G; Boyle E; Gay J; Manier S; Duthilleul P; Roumier C; Leleu X
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):202-4. PubMed ID: 23473949
[TBL] [Abstract][Full Text] [Related]
39. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
40. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
